Jiangsu Hengrui Pharmaceuticals and its partner Elevar Therapeutics will have to wait even longer before their PD-1 inhibitor ...

Findings on golidocitinib for patients with non-small cell lung cancer whose disease has progressed on anti-PD-1 therapy will ...

including a recent approval in neoadjuvant/adjuvant treatment of early-stage non-small cell lung cancer (NSCLC). It is the second drug in the PD-1/PD-L1 inhibitor class to be cleared in a ...

European regulators and payers may limit reimbursement to those patients who receive benefit from a drug ... PD-1 and PD-L1 immunotherapies in melanoma; similarly, a broad label in lung cancer ...

The FDA cleared the investigational new drug (IND) application for EVM14. EVM14 is an off-the-shelf tumor-associated antigen ...

The conversion from accelerated approval to traditional approval was supported by data from the phase 3 KEYNOTE-811 trial.

The FDA has approved Tevimbra with chemotherapy for the first-line treatment of unresectable or metastatic ESCC whose tumors express PD-L1.

Harry H. Yoon, MD, MHS, discusses tislelizumab and platinum-containing chemotherapy in unresectable or metastatic esophageal squamous cell carcinoma whose tumors express PD-L1 at a level of 1 or ...

A new cancer therapy utilising a genetically modified herpes simplex virus type 1 (HSV-1) offers hope for late-stage patients ...

Alphamab Oncology (stock code: 9966.HK) reported financial results for the full year ended December 31, 2024 and highlighted recent business progress.

PD-1, PD-L1, and VEGF inhibitors have been approved for over 50 indications in addition to NSCLC. Summit CEO Maky Zanganeh ...